Cargando…

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last decade, PPAR-γ agonists have received increasing attention for their neuroprotective properties displayed in a varie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carta, Anna R., Pisanu, Augusta, Carboni, Ezio
Formato:	Texto
Lenguaje:	English
Publicado:	SAGE-Hindawi Access to Research 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096077/ https://www.ncbi.nlm.nih.gov/pubmed/21603186 http://dx.doi.org/10.4061/2011/689181

Ejemplares similares

Metabolomics Fingerprint Induced by the Intranigral Inoculation of Exogenous Human Alpha-Synuclein Oligomers in a Rat Model of Parkinson’s Disease
por: Murgia, Federica, et al.
Publicado: (2020)

Modeling Parkinson’s Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers
por: Boi, Laura, et al.
Publicado: (2020)

PPARγ Agonists in Adaptive Immunity: What Do Immune Disorders and Their Models Have to Tell Us?
por: da Rocha Junior, Laurindo Ferreira, et al.
Publicado: (2013)

PPAR Agonists and Cardiovascular Disease in Diabetes
por: Calkin, Anna C., et al.
Publicado: (2008)

Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson’s Disease
por: Palmas, Maria Francesca, et al.
Publicado: (2022)

Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver
por: Rogue, Alexandra, et al.
Publicado: (2010)

Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2(WD40) Genetic Model of Parkinson’s Disease
por: Casu, Maria Antonietta, et al.
Publicado: (2020)

PPAR-Alpha Agonists as Novel Antiepileptic Drugs: Preclinical Findings
por: Puligheddu, Monica, et al.
Publicado: (2013)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Apoptosis rate and transcriptional response of pancreatic islets exposed to the PPAR gamma agonist Pioglitazone
por: Lamounier, Rodrigo N, et al.
Publicado: (2013)

The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
por: Stunes, Astrid K, et al.
Publicado: (2011)

PPARα Agonist Oral Therapy in Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020)

Dyskinesia in Parkinson's Disease Therapy
por: Carta, Anna Rosa, et al.
Publicado: (2012)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?
por: Carboni, Elena, et al.
Publicado: (2020)

PPAR Gamma: From Definition to Molecular Targets and Therapy of Lung Diseases
por: de Carvalho, Márcia V., et al.
Publicado: (2021)

PPAR Gamma Agonist Leriglitazone Recovers Alterations Due to Pank2-Deficiency in hiPS-Derived Astrocytes
por: Santambrogio, Paolo, et al.
Publicado: (2023)

Profound Modification of Fatty Acid Profile and Endocannabinoid-Related Mediators in PPARα Agonist Fenofibrate-Treated Mice
por: Murru, Elisabetta, et al.
Publicado: (2022)

Sustained relief of trigeminal neuropathic pain by a blood–brain barrier penetrable PPAR gamma agonist
por: Zhang, Morgan, et al.
Publicado: (2019)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis
por: Zhang, Zhuo-Ya, et al.
Publicado: (2023)

Role of PPARα and Its Agonist in Renal Diseases
por: Cheng, Ching-Feng, et al.
Publicado: (2010)

PPAR agonists as therapeutics for CNS trauma and neurological diseases
por: Mandrekar-Colucci, Shweta, et al.
Publicado: (2013)

Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases
por: Khuchua, Zaza, et al.
Publicado: (2018)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Effects of a PPAR -gamma receptor agonist and an angiotensin receptor antagonist on aortic contractile responses to alpha receptor agonists in diabetic and/or hypertensive rats
por: Tugrul, Ibrahim, et al.
Publicado: (2016)

Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?
por: Carboni, Ezio, et al.
Publicado: (2021)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function
por: Gray, Elizabeth, et al.
Publicado: (2012)

PPAR Gamma agonists regulate tobacco smoke-induced toll like receptor 4 expression in alveolar macrophages
por: Yin, Yan, et al.
Publicado: (2014)

PPAR-gamma agonist pioglitazone recovers mitochondrial quality control in fibroblasts from PITRM1-deficient patients
por: Di Donfrancesco, Alessia, et al.
Publicado: (2023)

The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria
por: Serghides, Lena
Publicado: (2012)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

Selective PPAR-Delta/PPAR-Gamma Activation Improves Cognition in a Model of Alzheimer’s Disease
por: Steinke, Ian, et al.
Publicado: (2023)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?
por: Scatena, Roberto, et al.
Publicado: (2008)

PPAR Gamma and Hepatic Stellate Cells
por: Hazra, Saswati, et al.
Publicado: (2004)

The Role of PPAR Gamma in Systemic Sclerosis
por: Dantas, Andréa Tavares, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_229hs0m5lbj8mj8s0t291od1fp